Psychotogenic Drug Use and Neuroleptic Response

Bowers, Malcolm B.; Mazure, Carolyn M.; Nelson, J. Craig; Jatlow, Peter

doi:10.1093/schbul/16.1.81

Cited by 126 publications

(58 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The older antipsychotics (typical antipsychotics) are associated with movement disorders and neurologic side effects (Stroup, Kraus, & Marder, 2006) and tend to have modest ability to improve negative symptoms of schizophrenia (reduced motivation, emotion, and communicativeness) (Corrigan, Reinke, Landsberger, Charate, & Toombs, 2003). Moreover, the typical antipsychotics are thought to be only modestly helpful in dual disorder patients (Bowers, Mazure, Nelson, & Jatlow, 1990): they do not decrease substance abuse in these patients, and there is some suggestion that they may even worsen substance abuse in some of them (Brady et al, 1990;Dixon, Haas, Weiden, Sweeney, & Frances, 1991;McEvoy, Freudenreich, Levin, & Rose, 1995).…”

Section: Use Of Medications In Patients With Schizophrenia and Co-occmentioning

confidence: 99%

Substance abuse and schizophrenia: Pharmacotherapeutic intervention

Green¹,

Noordsy²,

Brunette³

et al. 2008

Journal of Substance Abuse Treatment

120

View full text Add to dashboard Cite

Substance use disorder is common in patients with schizophrenia and dramatically worsens their outcome. The typical antipsychotic medications, introduced over 50 years ago, are effective for the treatment of psychosis but may have only limited efficacy in patients with these co-occurring disorders because patients continue to use substances while taking them. In preliminary studies, however, several of the atypical antipsychotic medications have shown promise for reducing alcohol and drug use in patients with schizophrenia. A neurobiologic formulation is discussed, suggesting that the use of substances in patients with schizophrenia may be based on a dysfunction within the dopamine-mediated brain reward circuitry, and that clozapine in particular, may potentially ameliorate this dysfunction and lessen the desire for substance use. Medications for the treatment of alcohol use disorders, such as disulfiram, naltrexone and acamprosate, as well as other adjunctive medications, may also be useful. Further studies are required to establish a solid evidence base of best practices for the use of medications in these patients.

show abstract

Section: Use Of Medications In Patients With Schizophrenia and Co-occmentioning

confidence: 99%

Substance abuse and schizophrenia: Pharmacotherapeutic intervention

Green¹,

Noordsy²,

Brunette³

et al. 2008

Journal of Substance Abuse Treatment

120

View full text Add to dashboard Cite

show abstract

“…15 Comorbidity of substance use in schizophrenia has been associated with adverse outcomes, including higher symptom ratings, poor treatment responses, relapses, frequent hospitalisation, non-adherence, tardive dyskinesia, HIV infection, hepatitis C infection, suicide, and a range of psychosocial difficulties such as violence, victimisation, incarceration, homelessness and family problems. 12,[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] Other studies, however, have contradicted these findings or failed to identify robust relationships between the severity of schizophrenic symptoms and substance misuse. 1,12,[32][33][34][35][36][37] Some studies have failed to show the Aims and method To explore the patterns of alcohol consumption and its impact on clinical outcomes in schizophrenia in low-and middle-income countries.…”

mentioning

confidence: 99%

Alcohol use in schizophrenia: prevalence, patterns, correlates and clinical outcomes in Goa, India

et al. 2012

View full text Add to dashboard Cite

Aims and methodTo explore the patterns of alcohol consumption and its impact on clinical outcomes in schizophrenia in low- and middle-income countries. We performed a cross-sectional survey of 315 patients with schizophrenia and calculated the prevalence of alcohol consumption and alcohol use disorder. The patients' sociodemographic profiles and clinical outcomes, including Brief Psychiatric Rating Scale (BPRS) scores, were compared between abstainers and drinkers using the χ2- andt-tests.ResultsThe 1-year prevalence of drinking, hazardous drinking and alcohol dependence was 16.8% (95% CI 12.9–21.4), 5.7% (95% CI 3.4–8.9) and 2.5% (95% CI 1.1–4.9), respectively. Male gender, single or post-marital status, higher education and being economically active were significantly associated with alcohol consumption. Alcohol drinkers were significantly more likely to be on combination psychotropics compared with abstainers. The mean total BPRS score was significantly lower in alcohol drinkers compared with abstainers. Drinking alcohol was associated with fewer deficit symptoms.Clinical implicationsCultural settings have a significant impact on the prevalence of alcohol use disorder in schizophrenia.

show abstract

“…Pek çok şizofreni tanılı hasta için etkin bir tedavi grubunu oluşturmaktayasa da eştanılı www.cappsy.org şizofreni hastalarında bu ajanlar reçetelendiği zaman madde kullanımının devam ettiği ve klinik gidişin zayıf olduğu bildirilmiştir. [61][62][63][64] Ekstrapiramidal yan etkiler başta olmak üzere, şizofreni tanılı hastalar pek çok yan etki yaşamaktadırlar. [63] Tipik antipsikotiklerle madde kullanımının artış göster-diğini bildiren çalışmalar mevcuttur.…”

Section: Tedavi Psikoterapiunclassified

Substance Use Disorder Comorbidity in Schizophrenia

Aras¹

2013

Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychia

View full text Add to dashboard Cite

ÖZETŞizofreni tanısı alan hastalarda alkol ve madde kullanımı yaygındır. Şizofreni-de alkol madde kullanım bozuklukları sıklığı yüksek olmasına rağmen yapılan tüm çalışmalarda madde kullanım ektanısının dışlanması bu alandaki verilerin çok kısıtlı olmasına yol açmıştır. Yüksek eştanılılığın açıklanmasında pek çok teori öne atılmıştır. Tipik antipsikotik ilaçların şizofreni tanılı hastalarda alkol ve madde kullanımına etkileri sınırlıdır. Atipik antipsikotik ilaçların özellikle klozapin kullanımının etkinliği gösterilmiştir. Literatüre baktığımızda, alkol kötüye kullanımı tedavisinde pek çok yeni ajan ortaya çıkmışsa da, sadece bir tanesinin (naltrekson) şizofreni tanılı hastalarda kullanımına dair çalışmalar mevcuttur. Bu hasta populasyonunda, farmakolojik yaklaşımların tek başına en uygun fayda getireceğini düşünmek doğru bir yaklaşım olmaz. Psikoterapinin de içerisinde bulunduğu, iyi koordine edilmiş bir tedavi planı mutlak hedef olmalıdır. Anahtar Sözcükler: Şizofreni, alkol-madde kullanım bozukluğu, eştanılılık. ABSTRACTUse of alcohol and other substances are commonly observed among patients with a diagnosis of schizophrenia. Despite this common comorbidity, there have been very few studies which do not take alcohol/substance use as an exclusion criterion. Thus we have very limited data on this specific area. A number of theories have been developed to explain these high comorbidity rates. Typical antipsychotic medications decreases alcohol or substance use in general, but this is valid only for a limited extend in patients with schizophrenia. On the other hand atypical antipsychotics, particularly clozapine plays an active role in that respect. Recently, we can see lots of new adjunctive medications formulated for the treatment of alcoholism, but only one of them (naltrexone) has thus far been carefully studied and tested in relation with these ©2013, Psikiyatride Güncel Yaklaşımlar eISSN:1309-0674 pISSN:1309-0658

show abstract

Psychotogenic Drug Use and Neuroleptic Response

Cited by 126 publications

References 15 publications

Substance abuse and schizophrenia: Pharmacotherapeutic intervention

Substance abuse and schizophrenia: Pharmacotherapeutic intervention

Alcohol use in schizophrenia: prevalence, patterns, correlates and clinical outcomes in Goa, India

Substance Use Disorder Comorbidity in Schizophrenia

Contact Info

Product

Resources

About